<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278213</url>
  </required_header>
  <id_info>
    <org_study_id>T-PLL1</org_study_id>
    <secondary_id>EU-20562</secondary_id>
    <nct_id>NCT00278213</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia</brief_title>
  <official_title>Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and
      mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Giving more than one drug (combination
      chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as alemtuzumab, can
      block cancer growth in different ways. Some block the ability of cancer cells to grow and
      spread. Others can find cancer cells and help kill them or carry cancer-killing substances to
      them. Combination chemotherapy followed by alemtuzumab may be effective in treating chronic
      lymphocytic leukemia and prolymphocytic leukemia.

      PURPOSE: This phase II trial is studying how well giving combination chemotherapy followed by
      alemtuzumab works in treating patients with T-cell chronic lymphocytic leukemia or
      prolymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the number of severe adverse events and life-threatening infections in
           patients with T-cell chronic lymphocytic leukemia or T-cell prolymphocytic leukemia
           treated with induction chemotherapy comprising fludarabine, cyclophosphamide, and
           mitoxantrone hydrochloride followed by consolidation therapy comprising alemtuzumab.

        -  Determine the remission rate in patients treated with this regimen.

      Secondary

        -  Determine the overall and progression-free survival of patients treated with this
           regimen.

        -  Determine the quality of remission in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive induction chemotherapy comprising fludarabine IV and cyclophosphamide IV for
      3 days and mitoxantrone hydrochloride IV on 1 day. Treatment repeats every 28 days for up to
      4 courses. Patients then receive consolidation therapy comprising alemtuzumab IV 3 times in
      week 1 and then weekly for up to 11 weeks.

      PROJECTED ACCRUAL: A total of 17 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects at 2 months after treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission rate at 2 months after treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 months after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 2 months after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission quality at 2 months after treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Prolymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of T-cell chronic lymphocytic leukemia (T-CLL) or T-cell prolymphocytic
             leukemia (T-PLL)

          -  Previously untreated disease OR patient may have received up to 2 therapies

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 6 months

          -  No severe organ dysfunction

          -  No other concurrent or previous neoplasm

          -  No autoimmune hemolytic anemia or thrombocytopenia

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior fludarabine, mitoxantrone hydrochloride, cyclophosphamide, or alemtuzumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Hopfinger</last_name>
    <role>Study Chair</role>
    <affiliation>Hanusch-Krankenhaus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeinen Krankenhaus Celle Kinderklinik</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital - Medical Klinik II</name>
      <address>
        <city>Duisburg</city>
        <zip>D-47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>D-99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Garmisch - Partenkirchen GmbH</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>N 82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Hof</name>
      <address>
        <city>Hof</city>
        <zip>95032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologische Praxis - Moenchengladbach</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftliche Schwerpunktpraxis - Osnabrueck</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritasklinik St. Theresia</name>
      <address>
        <city>Saarbrucken</city>
        <zip>D-66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Haematologie und Onkologie</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch - Onkologische Praxis Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum des Landkreises Loebau-Zittau GmbH</name>
      <address>
        <city>Zittau</city>
        <zip>02763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dcllsg.de/en/trial/tpll1/index.php</url>
    <description>Click here for more information about this study: T-PLL1 (German CLL Study Group)</description>
  </link>
  <results_reference>
    <citation>Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, DÃ¶hner H, Kandler G, Eichhorst B, Hallek M, Herling M. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013 Jun 15;119(12):2258-67. doi: 10.1002/cncr.27972. Epub 2013 Mar 19.</citation>
    <PMID>23512246</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

